Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Junmin Zhang, Jilei Zhang, Qing Liu, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 108050-108050
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response
Xuan‐Run Wang, Zebo Jiang, Cong Xu, et al.
Pharmacological Research (2022) Vol. 179, pp. 106198-106198
Closed Access | Times Cited: 51
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Yunkai Yang, Huan Zhang, Shanshan Huang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 709-709
Open Access | Times Cited: 27
RAS degraders: The new frontier for RAS-driven cancers
Taylor E. Escher, K.J.F. Satchell
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1904-1919
Open Access | Times Cited: 19
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor
Yan Lv, Zixuan Yang, Yiming Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2487-2511
Closed Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
Berberrubine as a novel TrxR inhibitor enhances cisplatin sensitivity in the treatment of non-small cell lung cancer
Yajun Chu, Qiuying Nie, Xiedong Zhou, et al.
Bioorganic Chemistry (2025) Vol. 158, pp. 108329-108329
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance
Ruth Nussinov, Hyunbum Jang
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 231-253
Closed Access | Times Cited: 12
Applications of machine learning in computer-aided drug discovery
SM Bargeen Alam Turzo, Eric R. Hantz, Steffen Lindert
QRB Discovery (2022) Vol. 3
Open Access | Times Cited: 17
KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer
Ella Ä. Eklund, Clotilde Wiel, Henrik Fagman, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2063-2063
Open Access | Times Cited: 16
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
William J. McDaid, L Wilson, Helen Adderley, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
Christophe Bontoux, Véronique Hofman, Patrick Brest, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1628-1628
Open Access | Times Cited: 12
Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C
Haiming Zhuang, Jigang Fan, Mingyu Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis
Ling-Yu Zhu, Jun-Bo Yuan, Li Zhang, et al.
Cancer Research (2022) Vol. 82, Iss. 22, pp. 4153-4163
Open Access | Times Cited: 11
In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis
Gao Tu, Qing Liu, Yue Qiu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13845-13845
Open Access | Times Cited: 11
Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
Jiaxin Li, Runze Li, Lin-Rui Ma, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 9
Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression
Junmin Zhang, Pei Liu, Jianwei Chen, et al.
Pharmacological Research (2022) Vol. 187, pp. 106565-106565
Open Access | Times Cited: 9
Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy
Junmin Zhang, Jilei Zhang, Elaine Lai‐Han Leung, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 2, pp. 101-106
Closed Access | Times Cited: 4
Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience
Anna K. Rekowska, Piotr Rola, Agnieszka Kwiatkowska, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 325-325
Open Access | Times Cited: 1
Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy
Rita Nogueiras‐Álvarez, Inês Francisco
British Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 1
KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 5, pp. 752-754
Open Access | Times Cited: 5
The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
Chun-Lu Shu, Yuling Liu
Cancer Management and Research (2022) Vol. Volume 14, pp. 3485-3492
Open Access | Times Cited: 4
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Parneet Cheema, Shantanu Banerji, Normand Blais, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6473-6496
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top